Study Confirms Benefit of Regorafenib in Previously Treated Metastatic Colorectal Cancer
the ONA take:
According to research presented at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona, Spain, researchers have confirmed that regorafenib is beneficial for the treatment of patients with previously treated metastatic colorectal cancer.
The phase III CORRECT study previously demonstrated a significant improvement in progression-free survival in patients with previously treated metastatic colorectal cancer. For the phase IIIb CONSIGN trial, researchers prospectively assessed the efficacy and safety of regorafenib in patients with pre-treated metastatic colorectal cancer before marketing of the drug was authorized.
The study showed that the estimated progression-free survival was 2.7 months and there were no surprising findings in regard to adverse events.
The CONSIGN trial is significant in that its patient population more closely resembled a real world population of patients compared with the CORRECT trial
"CONSIGN confirms the efficacy and safety data of the randomised phase III CORRECT and CONCUR trials. The merit of CONSIGN is that it translates phase III data into the clinical routine since patients had similar characteristics and pre-treatment to what we see in daily practice," Dirk Arnold, MD, ESMO spokesperson, director of the Department of Medical Oncology, Klinik für Tumorbiologie in Freiburg, Germany, said.
Researchers have confirmed that regorafenib is effective for the treatment of previously treated metastatic colorectal cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|